Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $12.76
Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $12.76
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating)'s share price gapped up prior to trading on Monday . The stock had previously closed at $12.76, but opened at $13.08. Janux Therapeutics shares last traded at $12.60, with a volume of 106 shares.
JANUX治疗公司(纳斯达克代码:JANX-GET评级)的股价在周一交易前大幅上涨。该股此前收盘报12.76美元,但开盘报13.08美元。JANUX治疗公司的股票最后交易价格为12.60美元,成交量为106股。
Janux Therapeutics Stock Performance
Janux Treateutics股票表现
The stock has a fifty day moving average of $13.36 and a 200 day moving average of $13.07. The company has a market capitalization of $533.29 million, a P/E ratio of -10.10 and a beta of 1.69.
该股的50日移动均线为13.36美元,200日移动均线为13.07美元。该公司市值为5.3329亿美元,市盈率为-10.10,贝塔系数为1.69。
Janux Therapeutics (NASDAQ:JANX – Get Rating) last announced its earnings results on Tuesday, August 9th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.04). Janux Therapeutics had a negative return on equity of 15.10% and a negative net margin of 809.63%. The company had revenue of $2.37 million during the quarter. Research analysts anticipate that Janux Therapeutics, Inc. will post -1.74 EPS for the current fiscal year.
JANUX治疗公司(纳斯达克代码:JANX-GET评级)上一次公布收益结果是在8月9日星期二。该公司公布了该季度每股收益(0.41美元),低于分析师普遍预期的(0.37美元)和(0.04美元)。雅诺治疗公司的净资产回报率为负15.10%,净利润率为负809.63%。该公司本季度的收入为237万美元。研究分析师预计,Janux治疗公司本会计年度的每股收益将达到1.74美元。
Institutional Investors Weigh In On Janux Therapeutics
机构投资者对Janux治疗公司的看法
Janux Therapeutics Company Profile
Janux治疗公司简介
(Get Rating)
(获取评级)
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Janux治疗公司是一家生物制药公司,开发基于专有的肿瘤激活T细胞激活器(TRACTr)平台技术的疗法,用于治疗癌症患者。该公司处于临床前或发现阶段的主要候选TRACTr产品针对前列腺特异性膜抗原、表皮生长因子受体和滋养层细胞表面抗原2。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- 免费获取StockNews.com关于Janux治疗公司的研究报告(Janx)
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
- 自动区重新进入拉力赛模式,新高在望
- Upwork股价跌入便宜货领域
- 克罗格百货是你的一站式消费者史泰博股票
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得Janux治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Janux治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。